ERAS

Erasca, Inc.

• Simply Wall St·1d ago

  Erasca (ERAS) Is Up 9.9% After Merck Tie-Up And IP Challenge To ERAS-0015 - Has The Bull Case Changed?

• PR Newswire·3d ago

  Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset

• Simply Wall St·3d ago

  Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus

• PUBT·6d ago

  Erasca releases corporate presentation outlining RAS/MAPK cancer drug pipeline

• The Motley Fool·6d ago

  Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally

• The Motley Fool·05/17 18:18

  Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

• Seeking Alpha·05/17 11:29

  Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

• The Motley Fool·05/16 15:01

  Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

• Simply Wall St·05/16 14:38

  Assessing Erasca (ERAS) Valuation After ERAS-0015 Patent And Trade Secret Dispute

• The Motley Fool·05/14 18:51

  Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%

• TipRanks·05/14 16:11

  Adlai Nortye initiated with a Buy at JonesResearch

• TipRanks·05/14 12:12

  J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

• Simply Wall St·05/13 20:59

  The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift

• Seeking Alpha·05/12 15:01

  Healthcare stocks with A+ momentum investors are watching

• Dow Jones·05/12 13:11

  Erasca Price Target Cut to $26.00/Share From $28.00 by Mizuho